Recent Downgrade Insights on Abercrombie & Fitch and Bath & Body Works
In the ever-changing retail landscape, consumer behaviors are reshaping what once seemed certain. Recent insights from JPMorgan underscore this trend as analyst Matthew R. Boss takes a more cautious stance on Abercrombie & Fitch Company (NYSE: ANF) and Bath & Body Works, Inc. (NYSE: BBWI). Following thorough fieldwork and feedback from management, JPMorgan has made notable downgrades.
Understanding Current Consumer Spending Trends
The analyst revealed that consumer spending in the U.S. increased by 3.6% year over year for September. This figure marks a decrease from previous rates of 4.7% in August and 4.4% in July, although it remains higher than the 3.4% six-month average spanning January to June 2025.
The Impact on Apparel and Footwear Spending
When analyzing the numbers further, it was noted that apparel and footwear saw a year-over-year spending rise of 4.6% in September, down from August's 6.7%. Despite this decrease, it is still slightly above the first-half average of 4.3%.
Resilience in Consumer Behavior Despite Challenges
Overall, consumer spending has shown resilience, with significant boosts in July and August attributed to favorable year-over-year comparisons and back-to-school demand. The growth observed in September remains above pre-July averages, signaling a steady momentum in consumer confidence.
Details Surrounding Abercrombie & Fitch's Downgrade
As a result of his findings, Boss has downgraded Abercrombie & Fitch from Overweight to Neutral, while maintaining his price target at $103. The revenue growth estimates for the third and fourth quarters have been reduced below consensus expectations, forecasting only 3.9% growth in quarter three, significantly lower than the projected 6.2% from the market.
Challenges Affecting Abercrombie's Performance
Moreover, Boss indicated that the weaker-than-expected performance by Abercrombie was due to challenges in conversion rates and average unit retail pressure, despite enjoying strong traffic.
Future Projections for Abercrombie's Financials
The outlook for the fourth quarter is similarly troubled, with same-store sales anticipated to decline by 7%, a stark contrast to the Street's more optimistic view of a mere 0.8% decline. Furthermore, predictions for earnings reflect these challenges: $1.95 for the third quarter—12% below the Street's estimates and below management's guidance—while the fourth quarter is set at $3.23, about 11% under expectations.
Analyzing Bath & Body Works' Situation
Likewise, Bath & Body Works also faced a downgrade from Overweight to Neutral, with a consistent price target of $26. Boss modified the third-quarter revenue growth forecast down to -0.6% year-over-year, marking it significantly below both management's midpoint guidance and market consensus.
Projected Financials for Bath & Body Works
EPS estimates for the third quarter are revised to $0.34—20% below market expectations. The fourth quarter estimate now stands at $2.03, approximately 10% under market forecasts, resulting in an annual projection of $3.21.
The Market Response to Recent Developments
In light of these downgrades, Abercrombie & Fitch shares saw a decline of 6.96% to around $78.60, while Bath & Body Works experienced a slight increase of 2.11%, reaching $26.42 at the last check.
Frequently Asked Questions
1. What led to JPMorgan's downgrade of Abercrombie & Fitch?
The downgrade was a result of shifting consumer spending trends and challenges in conversion and average unit retail pressures.
2. How has consumer spending changed recently?
Consumer spending rose by 3.6% in September but has been declining from higher rates observed in earlier months.
3. What are the future earnings projections for Abercrombie & Fitch?
For FY25, GAAP EPS is projected at $9.68, lower than prior estimates.
4. What analyst ratings does Bath & Body Works currently hold?
Bath & Body Works is rated Neutral with a price forecast of $26 by JPMorgan.
5. How did the market respond to these downgrades?
Abercrombie & Fitch shares dipped by nearly 7%, while Bath & Body Works shares increased slightly by over 2%.
